LONDON, July 7 — A woman who was denied genetic testing for BRCA mutations until after her cancer diagnosis is now scheduled for a double mastectomy as part of her treatment, according to the source. The case, identified as that of Ellie Sullivan, illustrates a gap in preventive care that exists for some high-risk patients. For women who test positive for BRCA mutations, prophylactic mastectomy can reduce breast cancer risk by 90-95 percent, the source shows.
Prophylactic oophorectomy, the removal of the ovaries, reduces ovarian cancer risk by 80-90 percent and also lowers breast cancer risk if performed before menopause. The surgeries are typically offered to high-risk women after genetic counselling.
The NHS offers these surgeries to BRCA carriers, but Ellie’s case illustrates that without early testing, women may miss the opportunity for preventive surgery, according to the source. Her double mastectomy is scheduled as part of her treatment, not as a preventive measure.
The strategic context of genetic screening
The case raises questions about the timing of genetic screening within national health systems. The source shows that Sullivan was denied testing until after her diagnosis. Had she been tested earlier, the clinical pathway would have been different: preventive surgery rather than treatment for an existing condition.
The BRCA mutation is a known genetic marker that significantly elevates the lifetime risk of both breast and ovarian cancers. Prophylactic mastectomy, when performed on mutation carriers before any malignancy develops, offers the highest statistical reduction in risk.
The 90-95 percent figure is based on studies of women who underwent the procedure. Prophylactic oophorectomy carries a dual benefit, the source states. It reduces ovarian cancer risk by 80-90 percent.
For women who have the surgery before menopause, it also reduces breast cancer risk.
Access and timing
The NHS protocol for offering these surgeries to BRCA carriers is established, according to the source. However, the pathway depends on the patient being identified as a carrier before a cancer develops. Ellie Sullivan’s case shows what happens when that identification comes too late.
It does state that she is now scheduled for a double mastectomy as part of her treatment. That surgery is therapeutic, not preventive.
The distinction matters for both clinical outcomes and patient experience. The source presents Sullivan’s case as an illustration of a broader issue. Without early testing, women who carry the mutation may only learn of their genetic status after a tumour has already formed.
At that point, the window for preventive surgery has closed.
What to watch next
The case is likely to be cited in ongoing discussions about the expansion of genetic screening programmes in national health systems. The source does not indicate whether Sullivan has pursued any formal complaint or whether the NHS has reviewed its testing protocols in response to her case. Officials have confirmed that the NHS offers these surgeries to BRCA carriers, but the timing of testing remains the critical variable.
The clinical data on risk reduction from prophylactic surgery is well established. The question now is how to ensure that women who carry the mutation are identified early enough to benefit from it. Consult your doctor for medical advice.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Preventative Mastectomy And Oophorectomy Reduce BRCA Cancer Risk”, “description”: “LONDON, July 7 — A woman who was denied genetic testing for BRCA mutations until after her cancer diagnosis is now scheduled for a double…”, “datePublished”: “2026-07-07T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Dmitry Volkov”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
